The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-line of camrelizumab plus pyrotinib and chemotherapy in HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma: A dose escalation and expansion phase I study.
 
Liangjun Zhu
No Relationships to Disclose
 
Sheng Li
No Relationships to Disclose
 
Jun Bao
No Relationships to Disclose
 
Xiaoyou Li
No Relationships to Disclose
 
Quanliang Yang
No Relationships to Disclose
 
Junying Xu
No Relationships to Disclose
 
Surong Chen
No Relationships to Disclose
 
Ge Feng
No Relationships to Disclose
 
Chao Gao
No Relationships to Disclose
 
Lin Feng
No Relationships to Disclose
 
Bin Lu
No Relationships to Disclose
 
Min Miao
No Relationships to Disclose
 
Xinchu Ni
No Relationships to Disclose
 
Guofang Wang
No Relationships to Disclose
 
Lei Yang
No Relationships to Disclose